Landmark Reforms Hoped to Aid New York in the Fight against Opioid Addiction

It is hoped to be a happier new year for Empire State residents suffering from opioid abuse. In a landmark legislative package that took effect January 1st of this year, health insurance plans will now be required to cover treatment services to New Yorkers suffering opioid addiction. In a state plagued by the effects of opioids and heroin, whose overdose death rates are far outpacing nearly every state in the union, legislators are hopeful those grappling with the effects of these drugs can finally gain access to the help they need in overcoming addiction.

The Plan to Expand Access to Opioid Addiction Care

Signed into law by Governor Andrew M. Cuomo, the reforms are expected to remove burdensome treatment access barriers, help expand prevention strategies from within communities, and limit opioid over-prescriptions statewide. What is the governor’s Heroin and Opioid Task Force plan to stamp out abuse?

• Insurance-Related Protections
  • Insurance pre-authorization no longer required for immediate access to inpatient care and (emergency) drug treatment medications when needed.
  • Utilization review (insurance) cannot become involved until after 14 days of uninterrupted treatment.
  • Insurers must use objective, state-approved criteria when making coverage determinations.
  • Opioid-reversal medication coverage is mandated.
  • Requirements apply to small, large group, and individual plans regulated by the DFS.
• Addiction Treatment Services Enhancements
  • Individuals incapacitated by drugs can now receive 72, not 48 hours of emergency treatment and evaluation.
  • Hospitals are now required to provide follow-up service at discharge, connecting at-risk patients with nearby treatment options for continuous care.
  • Trained professionals no longer risk licensure when administering naloxone in emergencies.
  • Wraparound services (legal, support, transportation, childcare) have been expanded to support long-term recovery.
• Community Prevention Strategies
  • Prescription limits reduced from 30 to 7 day supply maximum (with exceptions).
  • Required continuing education for all physicians/prescribers on addiction/pain management.
  • Pharmacists must provide materials on addiction risks and nearby treatment services.
  • Opioid overdoses and overdose medication use must be reported quarterly.

Ensuring Appropriate Treatment Options For Opioid Addiction 

Much like the measures put forth by the state of New York, ANS Solutions’ Pharmacotherapy Review Program strives to uphold appropriate treatment options for patients, offering protection against opioid dangers with a three-stage approach to injury recovery that far-surpasses drug utilization review. Comprehensive and effective, it both protects against unnecessary expenses and safeguards patient treatment outcomes. Utilizing personal, face-to-face communication and integrative case-management methods, over-prescription of dangerous narcotics and potentially deadly drug-to-drug interactions commonly experienced with multiple prescribers can be prevented, success achieved with evidence-based treatment protocols and cemented by written proposal to achieve maximum results.

Don’t stand on the sidelines of the epidemic. Take part in the solution. Reinvent the way you handle claims with the help of ANS Solutions today.

Original content posted on http://ans-solutions.com/landmark-reforms-hoped-to-aid-new-york-in-the-fight-against-opioid-addiction/

Bipartisan Opioid Abuse Bill

In an effort to reverse the rapidly rising death toll from heroin, prescription drugs, and opioids across the U.S. which has recently risen to surpass automobile accidents as the leading cause of injury-related deaths according to the CDC, legislation has been drafted in a rare bipartisan effort.

The Comprehensive Addiction and Recovery Act (CARA)
Designed to strengthen prescription drug monitoring programs, better trace the diversion of opioid drugs, and increase promotion and access to addiction recovery services, CARA will also open up a variety of prevention and treatment avenues:

• Prevention and education efforts designed to prevent methamphetamine, opioid, and heroin abuse.
• Increased availability of Naloxone, an opioid overdose reversal agent, to first responders and law enforcement personnel.
• Disposal sites for unwanted prescriptions.
• Resources to identify and treat incarcerated individuals suffering opioid-related addiction disorders.

Well On Its Way
The bill has been approved by the House and the Senate, with both parties offering broad support. It is the first time in decades Congress has passed comprehensive addiction legislation, and the first time in history they’ve supported long-term addiction recovery. CARA is now on its way to the President’s desk, where it is expected to be signed into law. Mr. Obama has already requested $1.1 billion in funds toward the fight against opioid addiction.

Taking Action
Do you wish there was something you could do now to help in the fight against the nation’s continually rising opioid epidemic? You don’t have to wait on CARA to start making a difference. ANS Solutions proprietary Pharmacotherapy Review helps curtail costly and potentially dangerous pharmaceutical treatment regimens, ensuring optimal patient outcomes through expert knowledge and evidence-based, alternative treatment methods devised face-to-face with the help of treating doctors. Discover the difference an actionable drug utilization review can make. Contact http://www.ans-solutions.com today.

Original content posted on http://ans-solutions.com/bipartisan-opioid-abuse-bill/

Opioids Still the Top Prescribed Drug in California

Using data derived from the 10.8 million workers comp prescriptions dispensed between January 2005 and December 2014, a recently released report by the California Workers’ Compensation Institute identified opioids as the number one prescribed drug in California’s workers’ compensation system.

Report findings indicate that opioid prescriptions accounted for 27.2% of total prescribed pharmaceuticals. In addition, the average cost of opioid prescriptions rose by 85% from $61 to $113. In comparison, other prescription drugs within the same time frame experienced only a 39% increase, from $94 to $131. The report also indicated the proportion of injured workers prescribed opioids within the first 24 months following injury increased from 22.4% in 2005, to 27.9% in 2010.

Some positive trends were revealed however - in 2014, opioids dispensed to injured workers in the state dropped to 27.2%, from a 2009 peak of 31.9%. Also, the impending implementation of a statewide formulary is expected to contribute to reduced opioid use.

At the end of the day however, opioid use is still excessive. While prescription drug monitoring programs have been a focus of California state regulators, other California Workers’ Compensation Institute studies of utilization review have shown that medical management resources in California have been disproportionately directed to the review of requests for opioids and pain management drugs.

In workers’ compensation pain management, opioids continue to be prescribed in situations where their use may not be entirely appropriate, increasing the patient’s risk of addiction or overdose. ANS’s pharmacotherapy review program has been highly successful in uncovering overprescribing and ineffective management of patient treatment plans not just in California but across the country. The work of our legal nurse experts lays the ground work for pain treatment regimens that reduce the financial costs of large loss claims, while improving quality of care and life for injured workers.

To learn more about are success rate in California, contact ANS Solutions today.

This content was originally posted at http://ans-solutions.com/opioids-still-the-top-prescribed-drug-in-california/

Sources:

Hayes, Steve, Swedlow, Alex. “California Workers’ Compensation Institute: Trends in The USE of Opioids in California’s Workers’ Compensation System,” May 2016.

CDC Opioid Guidelines Sheds Light on Conflicting Expert Opinions

The CDCs latest opioid prescribing guidelines, released this March, were created with the goal of achieving balance between the analgesic and addictive properties of opioid analgesics, to uphold the safety as well as meet the pain management needs of the public at large. Unfortunately, the controversy surrounding these guidelines points to a detrimental issue at the crux of their implementation: A fractured field – two expert, yet conflicting, schools of thought on the current opioid policy.

• Treating chronic pain with a wider range of treatments, as opposed to relying mainly on opioid regimens.
• Avoiding the use of high dose prescriptions, as well as the combined prescription of opioids and benzodiazepines, to reduce the risk of overdose.
• Providing addiction treatment when necessary (methadone, buprenorphine).

There are two conflicting schools of thought regarding treatment approaches to opioids…

1. Reduce Pain and Suffering.
   This paradigm stems from an aggressive movement in the 1990s wherein physicians trained in pain management and palliative care were instructed to be sympathetic to pain. Enforced by the belief that those in true pain would not become addicted and reinforced by pharmaceutical companies and federal agencies pointing to pain as “the fifth vital sign,” this movement missed the boat on understanding the serious risks of opioid addiction.
2. Prevent and Treat Addiction.
   Driven by addiction specialists, who lacked an understanding of the seriousness of debilitating and chronic pain and whose priorities were vastly different than pain and palliative care physicians, practitioners of this model had a more thorough understanding of the addictive risks of opioid regimens. They watched the sales of opioid prescriptions quadruple from 1999-2010 - alongside the rate of overdose deaths. Though the need for a rapid public health response remained apparent, insufficient evidence on safe stoppage procedures for opioid regimens existed. Dissention among experts as to the seriousness of the problem and how to address also further muddied the waters.

The Fulcrum between Analgesia and Addiction

Though the CDC’s recently released guidelines are as strong as they can currently be, opioid pain treatment regimens – and addiction treatments – continue to be a work in progress. The fractured nature of this field reflects the reason changes were such a long time coming. A multidisciplinary approach will be as essential to working out the kinks as they were to the development of the CDC’s recently released guidelines, as all parties involved strive to save lives and ensure quality of care.

Are you looking for more advanced and comprehensive medical cost containment strategies that protect patient outcomes while also reducing the costs associated with pain management in workers compensation claims? ANS Solutions’ pharmacotherapy review program can help.

This content was originally posted at http://ans-solutions.com/cdc-opioid-guidelines-sheds-light-on-conflicting-expert-opinions/

Prescription Drug Abuse Knows No Bounds

Earlier this month, the American public was shocked by the untimely death of iconic pop legend Prince. Though autopsy results remain unreported, media coverage alleges that Prince was struggling with a prescription pill addiction to Percocet, receiving treatment for an opioid overdose just days before his death.

This post is not to re-hash celebrity news from various gossip reports but rather to point out the depth and breadth of the prescription drug epidemic. In the past decade, Whitney Houston, Heath Ledger, Brittany Murphy, Anna Nicole Smith and Michael Jackson were just a few other celebrities to overdose on legally prescribed medication. These very public deaths reflect a larger wave of prescription drug abuse across the United States, something ANS has touched on frequently in our blog posts.

A Proactive Approach to Patient Care

There seems to be a false sense of security that accompanies the use of doctor prescribed pain killers- the risk of addiction may not be stated clearly enough or is just not taken seriously.

At the end of the day opioid addiction knows no boundaries, spanning all races, ages, genders and income levels.

When it comes to chronic pain treatment, a focus on the education of well-being of the injured worker is crucial. That is why ANS developed pharmacotherapy review – not only as a medical cost containment strategy for payers, but as a proactive approach to minimizing inappropriate, duplicate or unnecessary treatment regimens, as is often seen with opioid based prescription pain killer treatment regimens.

Through in-depth reviews of each patient’s medical history alongside the assessment of the practices of prescribing physicians, our legal nurse experts are able to uncover underlying illnesses, behaviors and risks, and then implement actionable recommendations to existing treatment plans, addressing potential issues before they can lead to serious adverse events.

Concerned about the growing opioid epidemic and how it’s contributing to treatment outcomes and your large loss workman’s comp claims? We can help, contact ANS today at www.ans-solutions.com.

This content was originally posted at http://ans-solutions.com/prescription-drug-abuse-knows-no-bounds/

2016 WCRI Annual Issues & Research Conference

ANS recently attended the 2016 WCRI Annual Issues & Research Conference. The independent, not-for-profit institute studies and delivers objective information pertaining to public policy issues involving the workers’ comp system.

Conference Panel Highlights:

• Opioid Prescribing in Workers’ Comp
  • Overview:
    Opioids are a societal problem – not just a workers’ comp issue, and it will take a decade to dig ourselves out. Guidelines are necessary to combat the growing trend.
  • Positive Trends:
    Prescription frequency varies widely by state, leading to revised prescribing guidelines in medical/workers’ comp communities. Retail pharmacies are no longer simply filling, but verifying diagnosis/necessity. The DEA/FDA are also reclassifying some medications to reflect abuse potential, and activist groups supporting change are emerging.
  • Negative Trends:
    A major problem in the workers’ comp arena, the need for early intervention/monitoring is being overlooked by employers, and subsequently programs. Conflicting guidelines also cause confusion. Additionally, use of heroin, the cheaper alternative to prescription opioids, is on the rise.
  • Goals:
    Curtail chronic opioid use and ensure appropriate prescribing of opioids to injured workers and avoid unintended results by boosting awareness of the issue.
• Opioid Dispensing and Use
  • Overview:
    Yet-to-be published studies reveal the impact of pricing reforms for opioid dispensing physicians.
  • Physician Dispensing:
    Following reforms, prices decreased in most states, with fewer prescriptions dispensed. In IL and FL prices substantially increased – because physicians switched to formulations not covered in fee schedules. Price/amounts of pharmacy-dispensed products remained constant.
  • Variations in Use:
    Three-of-four injured workers nationwide receive opioids for pain. LA, NY, and PA dispense significantly higher amounts; NY and PA higher dosages. Patients who received opioids also received benzodiazepines in WI, MI, CT and MA. Per claim amounts decreased from 2012-2014, and frequency of drug testing increased significantly.

As an industry leader in large loss workers compensation claim management, ANS is setting the pace for drug utilization review with our proprietary Pharmacotherapy Review, helping fight the trend of the over-prescription of narcotics. Contact http://www.ans-solutions.com today.

This blog was originally posted at http://ans-solutions.com/2016-wcri-annual-issues-research-conference/

FDA Focuses on Opioid Policy

The FDA has recently acknowledged its own need to establish a “far-reaching action plan to reassess the agency’s approach to opioid medications” in order to reduce the trend, deemed by the U.S. Department of Health and Human Services as “a serious public health issue.” Now the leading cause of accidental death in the U.S., more Americans currently die from drug overdoses annually than motor vehicle crashes, the majority of which can be linked back to opioid prescription medications such as oxycodone, hydrocodone, codeine, morphine, fentanyl, and others.

National Attention

In addition to spurring the FDA to action, Health and Human Services Secretary Sylvia Burwell identified the boundlessness of the epidemic, citing the importance of both state and federal leaders coming together to form “a coordinated and comprehensive approach to address this crisis.” President Obama has also taken part in multiple efforts to curb the issue, including his 2010 National Drug Control Strategy to address opioid use disorders and overdose, as well as an October 2015 Memorandum to Federal Departments and Agencies calling for improved prescriber training and improved access to treatment for those addicted.

Recent Court Cases Press the Issue

The limelight on opioids has also triggered debate in the political arena, as well as even deeper scrutiny by the medical and workers’ comp communities, particularly following an array of eye-opening court cases in which doctors are being held liable for opioid prescribing practices. The most recent? February 2016’s Tseng Conviction, in which a California general practitioner was sentenced 30 years to life for the prescription of unnecessary painkillers which contributed to the fatal overdose of three patients.

The FDA Proposal to Combat the Epidemic

In response to the crisis, the FDA “has developed a comprehensive action plan to take concrete steps toward reducing the impact of opioid abuse on American families and communities.” Among the steps being taken…

• Advisory committees to review new drug applications, especially for opioids without abuse-deterrent properties.
• New warnings and safety labels to help doctors better understand risks and safe prescription practices.
• Upholding new requirements for drug companies to provide new data on the long-term impact of opioid drugs.
• Improved and updated CME training, including proven uses for opioids and safe prescribing practices, to decrease inappropriate prescriptions.
• Creating/expanding access to abuse-deterrent opioid formulations (ADF) to discourage abuse by spurring innovation, as well as generic formulations, of ADF products.
• A re-examination of the risk-benefit paradigm for opioids to include consideration of the widespread public health effects of drugs.

ANS Pharmacotherapy Review

Our approach to pharma review and intervention is the only face-to-face program of its kind offering evidence-based and actionable treatment recommendations that reduce pharma spend while offering improved quality of care for the injured worker with reduced risk of overdose and addiction. Contact http://www.ans-solutions.com to learn more about our comprehensive pharma review and intervention programs today.

This content was originally posted at http://ans-solutions.com/fda-focuses-on-opioid-policy/

SOURCES:

http://www.pbs.org/wgbh/frontline/article/how-bad-is-the-opioid-epidemic/

http://www.asam.org/docs/default-source/advocacy/opioid-addiction-disease-facts-figures.pdf

https://www.whitehouse.gov/the-press-office/2015/10/21/fact-sheet-obama-administration-announces-public-and-private-sector

http://www.hhs.gov/about/news/2015/09/17/hhs-hosts-50-state-convening-focused-preventing-opioid-overdose-and-opioid-use-disorder.html#

http://www.fda.gov/NewsEvents/Newsroom/FactSheets/ucm484714.htm

http://nationalpainreport.com/commentary-the-debate-over-opioids-should-be-much-more-than-it-is-8829446.html

http://www.consumerreports.org/cro/magazine/2014/09/the-dangers-of-painkillers/index.htm

6 Ways Pain Management is Mismanaged

There is a significant body of evidence suggesting that many Americans suffer from chronic pain and much of that pain is inadequately or ineffectively treated. Particularly in the case of chronic pain treatment via opioid analgesics, proper chronic pain management is critical in determining whether opioids are used in a manner that is both medically appropriate and in compliance with regulations. Pain management is an important area of patient care that is integral to the practice of medicine, yet so often it is mismanaged. Here we review six most common ways pain is mismanaged:

• Inadequate attention to patient education and informed consent. Deciding to begin opioid therapy for chronic pain should only be made after a physician and patient discuss the risks. Pain patients should have a clear understanding that the clinical basis for the use of these medications for chronic pain is limited, risk of addiction is real, and that taking opioids with other substances or certain conditions (i.e. depression or a history of substance abuse) may further increase risk.
• Inadequate attention to initial assessment. A proper assessment will help to determine if an opioid based pain treatment regime is medically appropriate and necessary. It will also help in uncovering risks associated with use for a particular individual.
• Inadequate monitoring during the use of habit forming medications. Due to its highly addictive and dangerous nature, opioids are associated with drug addiction and abuse. Chronic pain treatment benefit from opioid dose reductions or tapering or weaning off the opioid.
• Excessive reliance on opioids for chronic pain management without adequate attention to alternative treatments. Prescribers should use opioid therapy only when safer and equally as effective alternative therapies prove to be ineffective.
• Baseless dosage increases without adequate attention to risks or alternative treatments. The risks associated with opioids increase with higher doses and even more in conjunction with other comorbidities (i.e. mental illnesses, respiratory disorders, pre-existing substance use disorder and sleep apnea) and with concurrent use with respiratory depressants such as benzodiazepines or alcohol.
• Lack of utilization of available tools or lack of knowledge of available tools for risk mitigation. Our Pharmacotherpay Review program uncovers major issues including duplicate therapies, dangerous or deadly drug interactions, or behaviors related to drug addiction. All of which can have a dramatic impact on a patient’s health.

ANS Pharmacotherapy Review

A well informed physician’s practice can improve safety and the outcome of chronic pain treatment for patients. This is an area where the expert medical cost containment solutions of ANS Solutions can help. Our Pharmacotherapy Review Program provides three highly effective stages that not only contribute to lower medical costs in workers’ compensation claims, but greatly enhance the quality of life and care for injured workers.

For more information, visit www.ans-solutions.com.

This content was originally posted at http://ans-solutions.com/6-ways-pain-management-is-miss-managed/

Abuse Deterrent Opioids a New Era of Opioid Drug Development

The prevalence of opioid use and abuse has led to a new era of opioid drug development: Abuse deterrent (AD) opioids.

The goal?....

Maintain the efficacy of opioid formulations while improving their ability to deter abuse. Following guidelines developed by the FDA to categorize new opioid formulations, pharmaceutical companies are now on a quest to develop tomorrow’s safety net against opioid abuse.

How will the FDA be categorizing these new AD opioid formulations?

1. Physical/chemical barriers
   Physical barriers that prevent the crushing, cutting, grating, grinding, or chewing of opioid formulations, alone or in combination with chemical barriers, which can resist extraction with common solvents (water, alcohol, organic solvents).
2. Agonist/antagonist combinations
   Formulations with the addition of an opioid antagonist, released only when opioid drugs are manipulated. When triggered, the agonists “interfere with, reduce, or defeat” opioid induced euphoria commonly associated with abuse.
3. Aversion
   The addition of a noxious component to formulations to produce an unpleasant effect when opioids are manipulated, or when a higher dose than prescribed is consumed. (For example, a nasal irritant to deter snorting.)
4. Prodrug 
   Biologically inactive substances metabolized inside the body to their active form: That is, the drug must be taken by its intended route and form in order to be properly metabolized.
5. Delivery system
   The implementation of more difficult to manipulate drug delivery systems, such as subcutaneous implants, depot injectable formulations, beads within a capsule, and erodible matrix technology.
6. Combination of 2 or more of the above
   Combining 2 or more of the above methods to decrease the likelihood of abuse.

More questions than answers

Though AD technology is advancing, it continues to carry with it an onslaught of unmet expectations/unanswered questions…

• Is making an uncrushable pill really going to curb opioid abuse when it can be consumed in other ways?
• Why aren't efforts being made to explore more economically responsible, alternative therapies that don't involve any form of opioids at all?
• Will this approach yield enough penetration in the chronic pain treatment community to persuade physicians and patients to switch from their current prescriptions to abuse deterrent forms?

Helping curb the opioid epidemic

Only time will tell how the development of AD opioids will progress and effect the growing opioid abuse epidemic. Fortunately, you don’t have to await developing AD technology to take steps towards making a positive change. Readily available programs, including ANS expert nurse consulting and pharmacotherapy review can help you better address the need of pain patients, providing better outcomes, faster recovery times, and less risk than common opioid treatment regimens.

Ready to be part of the change? Contact ANS today and learn more about how ANS Pharmacotherapy Review can provide superior results for injured workers. Visit us at www.ans-solutions.com for more information.

This content was originally posted at http://ans-solutions.com/abuse-deterrent-opioids-a-new-era-of-opioid-drug-development/

Strategies to Reduce Patient Reliance on Opioids Postoperatively

Surgeons across the nation are increasing efforts to reduce their overall use of opioids for the long term treatment of chronic pain post-operatively. The driving force- Curtailing the opioid abuse epidemic, an unfortunate but growing trend.

Well-Documented Risks

An epidemic effecting 5 million Americans, half of all opioid-related overdose deaths in the U.S. have been linked to prescription drugs – not “street” or “recreational” drugs. Opioid use, even short term, is particularly problematic for patients with a history of substance abuse.

Changing Practices

Seeing the effects of this epidemic, many surgeons are taking steps to better help patients manage the healing process without potentiating future substance abuse issues. To that end, treatment strategies have emerged to reduce patient reliance on opioids postoperatively. Some of these methods include:

• A reduction in the use of opioids for the short-term management, including the time period two to three days post-op, to prevent the potential for abuse and misuse.
• Pre and perioperative treatment strategies designed to reduce patient reliance on opioids for moderate to severe post-op pain (commonly the first line of therapy).
• The implementation of patient pain contracts to engage patients in their own care and formally educate them on pain management, compliance, prescription use, and routine drug monitoring.
• ERAS (enhanced recovery after surgery) protocol, incorporating the use of short-acting anesthetics, nonsteroidal anti-inflammatory drugs (Exparel, Pacira), ileus control, invasive monitoring, and intensive care treatment combined with minimally invasive surgical techniques designed to enhance post-op recovery by preventing problems resulting from exaggerated inflammatory reactions to procedures (poor healing, infections, organ dysfunction). This technique has been associated with an improved postoperative length of stay and morbidity and reduced reliance on opioids post-operatively.

A Study in Possibilities

A recent study shows how even simple changes may affect opioid use. In the study, a pink reminder card was included in patient files to encourage hand surgeons to discuss with patients prior to surgery postoperative pain management options, explain the risk of opioids, and recommend alternatives. The card – and subsequent discussions - netted a 15% decrease in opioid prescriptions written. Likewise, a survey of dermatologic surgeons found 64% of surgeons prescribing opioids post-operatively for fewer than 10% of surgical patients.

Looking Ahead

While this is a good place to start in the fight against opioid epidemic, when it comes to chronic pain and workers compensation claims, a true drug utilization review program can also contribute to enhancing the quality of treatment and reducing medical costs. ANS Solutions drug utilization review program through pharmacotherapy review is the most advanced of its kind. To find out more about our effective medical cost containment strategies contact us today or visit www.ans-solutions.com.

This content was originally posted at http://ans-solutions.com/strategies-to-reduce-patient-reliance-on-opioids-postoperatively/

References

Dunleavy, Brian. Curbing Opioids Postoperatively, an Increasing Focus of Many Surgeons. PainMedicineNews.com; November 26, 2015.

The Perils of Polypharmacy

In the context of large loss workers compensation claims and the treatment of pain in injured workers, polypharmacy is typically associated with the use of four or more medications. As a result, polypharmacy creates an environment where several complications can occur. Here we delve into some critical issues affecting the injured worker as a result of polypharmacy: compliance, drug interaction and risk of addiction.

Dosage Compliance & Drug Interactions

To put it simply, compliance is taking medications the way they are intended to be taken. The lack of compliance with a prescribed treatment regimen is most often unintentional. A patient may inadvertently take the wrong dosage, miss a dosage entirely or mix dangerous combinations of drugs. Further, even though the right dosages may be administered, drug interaction poses yet another harmful risk for the injured worker. Treating physicians may not be communicating with each other and therefore are unaware of existing medications or treatment regimens which may affect quality of care. For example, MAO inhibitors and blood thinners can actually counteract or reduce another medication's effectiveness.

Possible Addiction & Overdose

Addiction and overdose are both related to treatment and dosage compliance. An unfortunate lack in monitoring a patient’s treatment program and progress may result in missed warning signs and missed opportunities to modify a treatment program based on patient’s recovery. Quite often addiction is not self-imposed but rather, factors such as duplicate therapies, inappropriate treatments and excessive dosages of opioids set the stage. Pain treatment through highly addictive opioids, coupled with a lack of patient education on the risks and dangers of these drugs, subjects injured workers to a path of drug addiction which may hinder or prevent recovery.

How Can ANS Solutions Pharmacotherapy Review Help?

Our Pharmacotherapy review program can help uncover possible risks that could have a dramatic impact on the person's health. Typically, Pharmacotherapy Review uncovers major issues including duplicate therapies, dangerous or deadly drug interactions, or behaviors related to drug addiction. All of which may contribute to a longer recovery time, no recovery or even death for an injured worker. By bringing these issues to light and recommending a more appropriate course of action our program can enhance the quality of life for the injured worker while also increasing financial cost for Payers.

To find out more about our Pharmacotherapy Review Program visit the website today at http://www.ans-solutions.com.

This post was originally published at http://ans-solutions.com/the-perils-of-polypharmacy/

What Role does the Doctor-Patient Relationship Play in the Opioid Epidemic?

According to the DEA, sales of prescription painkillers in the United States have quadrupled since 1999. If that isn’t enough to raise eyebrows, consider the following: almost twice as many people abuse prescription drugs as the number of people abusing cocaine, heroin, hallucinogens and inhalants combined. And if that’s that enough, the U.S. Center for Disease Control and Prevention has stated that prescription drug overdose death rates in the United States have more than tripled since 1990 and have never been higher. These statistics have raised serious concerns, triggering efforts to build competency around opioid prescription practices in the treatment of chronic pain.

The Doctor-Patient Relationship

The doctor-patient relationship must extend beyond merely establishing a treatment program. It should be treated as an intersection between education, treatment, intervention, and compliance that is formative in controlling the opioid epidemic. The dialogue between doctor and patient can help to uncover additional risk factors, warning signs, and complications that could hinder an injured worker’s recovery or put them at risk for addiction or death. Engaging in open conversation with patients regarding their medical history and other current treating physicians (if more than one) opens the door to more informed treatment practices. For instance, this practice would be instrumental in identifying a patient whose clinical picture is more consistent with addiction. In which case, the treating physician would be prompted to utilize a non-opioid treatment plan that may also be far more cost effective. Further, it is through this relationship that patients can receive the necessary education on the risks and dangers of their prescribed opioid pain treatment plan thus promoting adherence to prescription guidelines.

ANS Pharmacotherapy Review

In our pharmacotherapy review program we take a highly comprehensive and multidisciplinary approach to the evaluation and treatment of injured workers. Through our advanced techniques our experts are able to uncover opportunities for modifications that can improve patient efficacy. Our proven results not only improve the quality of care and life for the patient but also reduce associated medical costs.

For more information on ANS drug utilization review through pharmacotherapy contact us today or visit www.ans-solutions.com.

This content was originally posted at http://ans-solutions.com/what-role-does-the-doctor-patient-relationship-play-in-the-opioid-epidemic/

High Risk Patient Profiles & Opioid Abuse

Predictive models in our industry show that specific risk factors correlate to the potential for long term opioid use -most notably, patients that smoke and/or have a history of substance abuse.   With increased opioid prescribing linked to trends of misuse and abuse and opioid related overdoses contributing to more deaths annually than vehicular crashes, it begs the question, are risk factors truly being taken into account with the treatment of chronic pain?

Improving Opioid Painkiller Practices

Physicians considering opioid therapy for an injured worker with chronic pain should use a structured approach. There should be a comprehensive evaluation for the cause of pain, assessment for risk of opioid abuse or addiction, detailed treatment history including a review of medical records and routine assessment for safety and effectiveness of the opioid therapy program once in place. A dedicated focus on the patient will allow treating physicians to:

• Get ahead of the warning signs of drug abuse and addiction.
• Modify a treatment program based on patient’s recovery.
• Modify treatment based on the availability of alternative treatments and therapies that may be more effective, and have fewer side effects.
• Avoid unnecessary or inappropriate pharmaceutical and medical treatments in the event there are multiple treating physicians in the picture.

Risks should be acknowledged openly and managed, whenever possible, before prescribing opioids. When continuous opioid therapy for as little as two weeks can produce drug tolerance in some patients, the bottom line is, we need to start thinking more about the injured worker.

ANS Drug Utilization Review

Interventions with prescribers can be instrumental in not only preventing long term opioid use but also improving the quality of life and treatment for patients while also driving down medical costs. At ANS, our approach to drug utilization review includes an extensive review of a patient’s medical history allowing our experts to pinpoint risk factors and other considerations that are all too often overlooked by other medical cost management programs in the industry.

For more information about our medical cost containment strategies contact us today or visit www.ans-solutions.com.

This content was originally posted at http://ans-solutions.com/high-risk-patient-profiles-opioid-abuse/